Symbols / VXRT $0.65 -6.86% Vaxart, Inc.

Healthcare • Biotechnology • United States • OQX
VXRT Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Steven Lo
Exch · Country OQX · United States
Market Cap 157.77M
Enterprise Value 120.56M
Income 37.10M
Sales 255.61M
FCF (ttm) -31.73M
Book/sh 0.36
Cash/sh 0.25
Employees 65
Insider 10d —
IPO Dec 11, 1981
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 4.08
Forward P/E -0.97
PEG —
P/S 0.62
P/B 1.79
P/C —
EV/EBITDA 2.64
EV/Sales 0.47
Quick Ratio 1.54
Current Ratio 1.71
Debt/Eq 12.96
LT Debt/Eq —
EPS (ttm) 0.16
EPS next Y -0.67
EPS Growth —
Revenue Growth 87.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA 14.10%
ROE 53.10%
ROIC —
Gross Margin 21.14%
Oper. Margin 13.19%
Profit Margin 14.51%
Shs Outstand 241.97M
Shs Float 238.99M
Insider Own 1.34%
Instit Own 0.05%
Short Float 9.40%
Short Ratio 2.61
Short Interest 21.17M
52W High 0.84
vs 52W High -22.38%
52W Low 0.26
vs 52W Low 150.77%
Beta —
Impl. Vol. —
Rel Volume 0.68
Avg Volume 489.00K
Volume 330.90K
Target (mean) $3.00
Tgt Median $3.00
Tgt Low $2.00
Tgt High $4.00
# Analysts 2
Recom None
Prev Close $0.70
Price $0.65
Change -6.86%
About

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.00
Mean price target
2. Current target
$0.65
Latest analyst target
3. DCF / Fair value
$-2.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.65
Low
$2.00
High
$4.00
Mean
$3.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-03-27 main B. Riley Securities Buy → Buy $2
2024-08-15 init Oppenheimer — → Outperform $4
2024-01-31 up B. Riley Securities Neutral → Buy $2
2023-09-07 reit Cantor Fitzgerald Overweight → Overweight $4
2023-08-07 main Cantor Fitzgerald Overweight → Overweight $4
2022-12-19 main B. Riley Securities — → Neutral $2
2022-09-02 main Cantor Fitzgerald — → Overweight $8
2022-05-19 main B. Riley Securities — → Neutral $6
2021-11-02 init Cantor Fitzgerald — → Overweight $15
2021-06-30 down B. Riley Securities Buy → Neutral $9
2021-06-24 init Jefferies — → Buy $13
2021-06-11 init Piper Sandler — → Overweight $18
2020-08-12 main HC Wainwright & Co. — → Buy $17
2020-07-13 init B. Riley Securities — → Buy $22
2020-04-30 reit HC Wainwright & Co. — → Buy $7
2019-06-27 init HC Wainwright & Co. — → Buy $2
News
RSS: Latest VXRT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-23 BREITMEYER JAMES B Director — 78,800 — —
2026-03-16 TUCKER SEAN N. Officer — 200,000 — —
2026-03-16 CUMMINGS JAMES F. Officer — 227,000 — —
2026-03-16 BERG EDWARD B General Counsel — 115,000 — —
2026-03-16 GRASMAN JEROEN NICOLAAS Chief Financial Officer — 227,000 — —
2026-03-16 LO STEVEN Chief Executive Officer — 846,500 — —
2025-12-04 LO STEVEN Chief Executive Officer — 151,351 — —
2025-11-17 HERON ELAINE J Director — 40,000 $0.39 $15,921
2025-11-17 WATSON WILLIAM MARK Director — 20,000 $0.41 $8,185
2025-08-15 FINNEY KEVIN Director — 166,668 $0.35 $61,934
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
237.26
+726.68%
28.70
+288.94%
7.38
+6796.26%
0.11
Operating Revenue
237.26
+726.68%
28.70
+288.94%
7.38
+6796.26%
0.11
Operating Expense
219.18
+130.74%
94.99
+4.70%
90.73
-17.85%
110.44
Research And Development
201.58
+171.62%
74.21
+8.91%
68.14
-15.93%
81.05
Selling General And Administration
17.61
-15.26%
20.78
-7.99%
22.58
-23.15%
29.39
General And Administrative Expense
17.61
-15.26%
20.78
-7.99%
22.58
-23.15%
29.39
Other Gand A
17.61
-15.26%
20.78
-7.99%
22.58
-23.15%
29.39
Total Expenses
219.18
+130.74%
94.99
+4.70%
90.73
-17.85%
110.44
Operating Income
18.07
+127.26%
-66.29
+20.46%
-83.35
+24.46%
-110.33
Total Operating Income As Reported
18.07
+127.26%
-66.29
+20.46%
-83.35
+27.26%
-114.59
EBITDA
28.20
+151.40%
-54.87
+23.93%
-72.13
+28.28%
-100.58
Normalized EBITDA
28.20
+151.40%
-54.87
+23.93%
-72.13
+25.12%
-96.33
Reconciled Depreciation
8.58
-3.06%
8.85
+2.62%
8.62
+48.56%
5.80
EBIT
19.63
+130.80%
-63.72
+21.10%
-80.76
+24.09%
-106.39
Total Unusual Items
—
—
0.00
+100.00%
-4.25
Total Unusual Items Excluding Goodwill
—
—
0.00
+100.00%
-4.25
Special Income Charges
—
—
0.00
+100.00%
-4.25
Impairment Of Capital Assets
—
—
0.00
-100.00%
4.25
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
16.33
+124.39%
-66.95
+18.82%
-82.47
+23.47%
-107.76
Pretax Income
16.80
+125.20%
-66.69
+18.87%
-82.20
+23.67%
-107.69
Net Non Operating Interest Income Expense
-1.23
-188.03%
-0.43
-135.35%
1.21
+2177.59%
-0.06
Interest Expense Non Operating
2.82
-4.92%
2.97
+105.18%
1.45
+10.88%
1.30
Net Interest Income
-1.23
-188.03%
-0.43
-135.35%
1.21
+2177.59%
-0.06
Interest Expense
2.82
-4.92%
2.97
+105.18%
1.45
+10.88%
1.30
Interest Income Non Operating
1.60
-37.24%
2.54
-4.11%
2.65
+112.67%
1.25
Interest Income
1.60
-37.24%
2.54
-4.11%
2.65
+112.67%
1.25
Other Income Expense
-0.04
-241.94%
0.03
+150.00%
-0.06
-102.30%
2.70
Other Non Operating Income Expenses
-0.04
-241.94%
0.03
+150.00%
-0.06
-100.89%
6.95
Gain On Sale Of Security
—
—
—
-0.01
Tax Provision
0.48
+83.08%
0.26
-0.38%
0.26
+289.55%
0.07
Tax Rate For Calcs
0.00
-86.67%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-0.89
Net Income Including Noncontrolling Interests
16.33
+124.39%
-66.95
+18.82%
-82.47
+23.47%
-107.76
Net Income From Continuing Operation Net Minority Interest
16.33
+124.39%
-66.95
+18.82%
-82.47
+23.47%
-107.76
Net Income From Continuing And Discontinued Operation
16.33
+124.39%
-66.95
+18.82%
-82.47
+23.47%
-107.76
Net Income Continuous Operations
16.33
+124.39%
-66.95
+18.82%
-82.47
+23.47%
-107.76
Normalized Income
16.33
+124.39%
-66.95
+18.82%
-82.47
+21.01%
-104.40
Net Income Common Stockholders
16.33
+124.39%
-66.95
+18.82%
-82.47
+23.47%
-107.76
Diluted EPS
0.07
+121.21%
-0.33
+42.11%
-0.57
+32.14%
-0.84
Basic EPS
0.07
+121.21%
-0.33
+42.11%
-0.57
+32.14%
-0.84
Basic Average Shares
230.27
+13.92%
202.14
+39.58%
144.82
+13.42%
127.68
Diluted Average Shares
230.35
+13.96%
202.14
+39.58%
144.82
+13.42%
127.68
Diluted NI Availto Com Stockholders
16.33
+124.39%
-66.95
+18.82%
-82.47
+23.47%
-107.76
Gain On Sale Of PPE
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
186.08
+11.83%
166.39
+81.19%
91.83
Current Assets
136.12
+99.42%
68.26
+49.90%
45.54
Cash Cash Equivalents And Short Term Investments
63.81
+23.36%
51.72
+30.24%
39.71
Cash And Cash Equivalents
53.81
+113.30%
25.23
-27.41%
34.76
Cash Equivalents
50.23
+204.63%
16.49
-47.49%
31.40
Cash Financial
3.58
-59.00%
8.74
+160.74%
3.35
Other Short Term Investments
9.99
-62.28%
26.49
+434.37%
4.96
Receivables
51.34
+328.98%
11.97
+297.91%
3.01
Accounts Receivable
14.56
+152.80%
5.76
+91.52%
3.01
Other Receivables
36.78
+492.48%
6.21
—
Prepaid Assets
20.30
+377.74%
4.25
+71.23%
2.48
Restricted Cash
—
—
—
Other Current Assets
0.67
+109.75%
0.32
-4.50%
0.33
Total Non Current Assets
49.96
-49.09%
98.13
+111.97%
46.29
Net PPE
16.86
-42.06%
29.11
-20.40%
36.57
Gross PPE
30.67
-22.59%
39.62
-8.72%
43.40
Accumulated Depreciation
-13.80
-31.34%
-10.51
-53.83%
-6.83
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
1.14
+0.18%
1.14
+3.17%
1.10
Construction In Progress
0.16
-1.25%
0.16
+566.67%
0.02
Other Properties
25.44
-25.64%
34.21
-10.65%
38.29
Leases
3.93
-4.33%
4.11
+3.06%
3.98
Goodwill And Other Intangible Assets
7.33
-9.06%
8.06
-8.32%
8.80
Goodwill
4.51
+0.00%
4.51
+0.00%
4.51
Other Intangible Assets
2.83
-20.55%
3.56
-17.07%
4.29
Investments And Advances
—
—
—
Non Current Prepaid Assets
25.22
-58.05%
60.12
0.00
Other Non Current Assets
0.54
-35.76%
0.84
-9.40%
0.93
Total Liabilities Net Minority Interest
98.28
-8.55%
107.46
+215.84%
34.02
Current Liabilities
86.75
-4.54%
90.88
+562.18%
13.72
Payables And Accrued Expenses
65.13
+391.41%
13.25
+401.67%
2.64
Payables
21.50
+208.72%
6.96
+339.58%
1.58
Accounts Payable
21.50
+208.72%
6.96
+339.58%
1.58
Current Accrued Expenses
43.63
+593.61%
6.29
+494.61%
1.06
Pensionand Other Post Retirement Benefit Plans Current
4.24
-16.57%
5.09
+11.17%
4.58
Current Debt And Capital Lease Obligation
2.98
-3.22%
3.08
+13.84%
2.70
Current Capital Lease Obligation
2.98
-3.22%
3.08
+13.84%
2.70
Current Deferred Liabilities
13.02
-80.09%
65.40
0.00
Current Deferred Revenue
13.02
-80.09%
65.40
0.00
Other Current Liabilities
1.38
-65.99%
4.06
+6.76%
3.80
Total Non Current Liabilities Net Minority Interest
11.53
-30.50%
16.59
-18.30%
20.30
Long Term Debt And Capital Lease Obligation
6.01
-58.43%
14.45
-16.89%
17.39
Long Term Capital Lease Obligation
6.01
-58.43%
14.45
-16.89%
17.39
Non Current Deferred Liabilities
2.02
0.00
—
Non Current Deferred Revenue
2.02
0.00
—
Other Non Current Liabilities
3.50
+63.59%
2.14
-26.71%
2.92
Stockholders Equity
87.80
+49.00%
58.92
+1.94%
57.80
Common Stock Equity
87.80
+49.00%
58.92
+1.94%
57.80
Capital Stock
0.02
+4.35%
0.02
+53.33%
0.01
Common Stock
0.02
+4.35%
0.02
+53.33%
0.01
Preferred Stock
0.00
0.00
0.00
Share Issued
240.74
+5.49%
228.20
+48.22%
153.96
Ordinary Shares Number
240.49
+5.58%
227.77
+48.43%
153.45
Treasury Shares Number
0.25
-42.24%
0.43
-15.28%
0.51
Additional Paid In Capital
548.13
+2.31%
535.77
+14.55%
467.73
Retained Earnings
-460.19
+3.43%
-476.52
-16.35%
-409.57
Gains Losses Not Affecting Retained Earnings
-0.00
-175.00%
0.00
+500.00%
-0.00
Treasury Stock
0.16
-54.57%
0.35
-4.37%
0.37
Other Equity Adjustments
-0.00
-175.00%
0.00
+500.00%
-0.00
Total Equity Gross Minority Interest
87.80
+49.00%
58.92
+1.94%
57.80
Total Capitalization
87.80
+49.00%
58.92
+1.94%
57.80
Working Capital
49.37
+318.27%
-22.62
-171.10%
31.81
Invested Capital
87.80
+49.00%
58.92
+1.94%
57.80
Total Debt
8.98
-48.73%
17.53
-12.75%
20.09
Capital Lease Obligations
8.98
-48.73%
17.53
-12.75%
20.09
Net Tangible Assets
80.46
+58.21%
50.86
+3.78%
49.01
Tangible Book Value
80.46
+58.21%
50.86
+3.78%
49.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
7.71
+117.23%
-44.76
+36.46%
-70.45
+25.67%
-94.78
Cash Flow From Continuing Operating Activities
7.71
+117.23%
-44.76
+36.46%
-70.45
+25.67%
-94.78
Net Income From Continuing Operations
16.33
+124.39%
-66.95
+18.82%
-82.47
+23.47%
-107.76
Depreciation Amortization Depletion
8.58
-3.06%
8.85
+2.62%
8.62
+48.56%
5.80
Depreciation And Amortization
8.58
-3.06%
8.85
+2.62%
8.62
+48.56%
5.80
Other Non Cash Items
-2.70
-304.64%
-0.67
-194.08%
0.71
+112.23%
-5.81
Stock Based Compensation
8.31
-27.71%
11.50
-18.62%
14.13
+4.01%
13.59
Asset Impairment Charge
—
—
0.00
-100.00%
4.25
Operating Gains Losses
0.04
—
0.06
—
Gain Loss On Sale Of PPE
0.04
0.00
-100.00%
0.06
0.00
Change In Working Capital
-22.56
-791.69%
3.26
+130.06%
-10.85
-130.95%
-4.70
Change In Receivables
-39.38
-339.42%
-8.96
-199.90%
-2.99
-5958.82%
0.05
Changes In Account Receivables
-8.80
-219.76%
-2.75
+7.86%
-2.99
-5958.82%
0.05
Change In Prepaid Assets
18.80
+130.42%
-61.78
-1834.96%
3.56
+194.13%
-3.78
Change In Payables And Accrued Expense
48.37
+462.16%
8.61
+191.32%
-9.42
-217.70%
-2.97
Change In Accrued Expense
33.73
+912.45%
3.33
+147.74%
-6.98
-110.02%
-3.32
Change In Payable
14.64
+177.62%
5.27
+315.75%
-2.44
-784.59%
0.36
Change In Account Payable
14.64
+177.62%
5.27
+315.75%
-2.44
-784.59%
0.36
Change In Other Working Capital
-50.36
-177.00%
65.40
+3370.00%
-2.00
-200.00%
2.00
Investing Cash Flow
16.63
+178.00%
-21.32
-148.52%
43.95
+315.29%
-20.41
Cash Flow From Continuing Investing Activities
16.63
+178.00%
-21.32
-148.52%
43.95
+315.29%
-20.41
Net PPE Purchase And Sale
-0.14
+74.73%
-0.55
+68.36%
-1.75
+81.76%
-9.60
Purchase Of PPE
-0.14
+73.83%
-0.55
+70.39%
-1.87
+80.51%
-9.60
Sale Of PPE
0.01
0.00
-100.00%
0.12
0.00
Capital Expenditure
-0.14
+73.83%
-0.55
+70.39%
-1.87
+80.51%
-9.60
Net Investment Purchase And Sale
16.77
+180.75%
-20.77
-145.45%
45.70
+522.63%
-10.81
Purchase Of Investment
-23.23
+63.86%
-64.27
-133.73%
-27.50
+50.02%
-55.01
Sale Of Investment
40.00
-8.05%
43.50
-40.57%
73.20
+65.61%
44.20
Net Business Purchase And Sale
—
—
—
0.00
Purchase Of Business
—
—
—
0.00
Financing Cash Flow
4.24
-92.51%
56.56
+271.07%
15.24
-12.71%
17.46
Cash Flow From Continuing Financing Activities
4.24
-92.51%
56.56
+271.07%
15.24
-12.71%
17.46
Net Issuance Payments Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
4.25
-92.44%
56.29
+274.53%
15.03
-12.80%
17.24
Proceeds From Stock Option Exercised
0.18
-61.98%
0.48
-16.41%
0.58
+157.33%
0.23
Net Other Financing Charges
-0.20
+7.01%
-0.21
+41.53%
-0.37
—
Changes In Cash
28.59
+400.07%
-9.53
+15.38%
-11.26
+88.48%
-97.73
Beginning Cash Position
25.23
-27.41%
34.76
-24.47%
46.01
-67.99%
143.75
End Cash Position
53.81
+113.30%
25.23
-27.41%
34.76
-24.47%
46.01
Free Cash Flow
7.57
+116.70%
-45.32
+37.34%
-72.32
+30.71%
-104.38
Interest Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-0.28
+63.47%
-0.76
-15.48%
-0.66
-304.29%
-0.16
Common Stock Issuance
4.25
-92.44%
56.29
+274.53%
15.03
-12.80%
17.24
Issuance Of Capital Stock
4.25
-92.44%
56.29
+274.53%
15.03
-12.80%
17.24
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category